For the latest information about our services and visiting during COVID-19 click here

24 September 2020

Sheffield researchers contribute key data to global Covid-19 study


Researchers from Sheffield Teaching Hospitals NHS Foundation Trust have contributed important data to new global research which shows that the steroid hydrocortisone can significantly improve outcomes for severely ill patients with Covid19.

The results from the REMAP-CAP trial, which were published in the Journal of the American Medical Association (JAMA), found that patients receiving intensive care who were treated with a regular fixed dose of the steroid hydrocortisone for seven days had an improved chance of recovery, compared with the patients who were not treated with the steroid.

The research reinforces evidence that these inexpensive and widely available drugs improve survival of the sickest Covid-19 patients.

Sheffield Teaching Hospitals recruited patients into the practice-changing study – and had one of the highest recruitment figures achieved by a single NHS Trust across the country.

Professor Gary Mills, Professor of Critical Care Medicine at Sheffield Teaching Hospitals NHS Foundation Trust, said: “We are delighted to have played an important role in this vital study, which has had an immediate impact in guiding treatments for the sickest Covid19 patients. I would like to thank all the patients and their families who agreed to take part in the trial as without them advances in the care of patients with Covid19 would not have been possible. Other aspects of the REMAP-cap are also still continuing.”

Dr David Hughes, Medical Director for Sheffield Teaching Hospitals NHS Foundation Trust, said: “The findings of this study once again highlight how vitally important clinical research is in helping us to find effective treatments for Covid-19. I am extremely proud of Sheffield’s contribution in this world-leading study and the incredible effort of our NIHR Clinical Research Facility, whose coordinated efforts with doctors and nurses across the Trust enabled eligible patients to access this life-changing steroid. We look forward to continuing to work with researchers and colleagues across the globe to further build high quality evidence that can benefit coronavirus patients in the future.”

The REMAP-CAP study is being conducted across 15 countries around the world and is being led in the UK from the National Institute for Health Research’s Imperial Biomedical Research Centre. The study uses an innovative ‘adaptive’ approach where information from patients already participating in the study can be used to help guide the treatment of new patients joining the study. Most trials are not able to do this.

Patients enrolled in the UK trial were being cared for at 88 hospitals including the Northern General Hospital and the Royal Hallamshire Hospital.


ENDS

Photo: The Royal Hallamshire Hospital
 

 



Go back
 
Rate this page: